ABVC BioPharma, Inc. (ABVC)

0.83 +4.27% (+0.03)

Over 3Y: -50.9%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

2 4
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 99K Q3 '21 — Operating Cash Flow: -2.2M Q3 '21 — Net Income: -1.8M Q4 '21 — Operating Cash Flow: -2.5M Q4 '21 — Free Cash Flow: -2.5M Q4 '21 — Net Income: -7.9M Q1 '22 — Revenue: 25.7K Q1 '22 — Operating Cash Flow: -3M Q1 '22 — Free Cash Flow: -3.1M Q1 '22 — Net Income: -6M Q2 '22 — Revenue: 312.9K Q2 '22 — Operating Cash Flow: -3.4M Q2 '22 — Free Cash Flow: -3.5M Q2 '22 — Net Income: -1.9M Q3 '22 — Revenue: 42.3K Q3 '22 — Operating Cash Flow: -513.7K Q3 '22 — Free Cash Flow: -518.1K Q3 '22 — Net Income: -3.7M Q4 '22 — Revenue: 589K Q4 '22 — Operating Cash Flow: -461.1K Q4 '22 — Free Cash Flow: -461.2K Q4 '22 — Net Income: -4.9M Q1 '23 — Revenue: 128.3K Q1 '23 — Operating Cash Flow: -1.5M Q1 '23 — Net Income: -1.8M Q2 '23 — Revenue: 6.1K Q2 '23 — Operating Cash Flow: -899.8K Q2 '23 — Net Income: -2.3M Q3 '23 — Revenue: 15.9K Q3 '23 — Operating Cash Flow: -1.4M Q3 '23 — Net Income: -3.3M Q4 '23 — Revenue: 2.2K Q4 '23 — Operating Cash Flow: -430.5K Q4 '23 — Free Cash Flow: -430.5K Q4 '23 — Net Income: -383.3K Q1 '24 — Revenue: 1.2K Q1 '24 — Operating Cash Flow: -955.8K Q1 '24 — Net Income: -2.8M Q2 '24 — Revenue: 117.1K Q2 '24 — Operating Cash Flow: -211.4K Q2 '24 — Net Income: -942.3K Q3 '24 — Revenue: 389.3K Q3 '24 — Operating Cash Flow: 60.2K Q3 '24 — Net Income: -394.8K Q4 '24 — Revenue: 2K Q4 '24 — Operating Cash Flow: -702.1K Q4 '24 — Net Income: -731.6K Q1 '25 — Operating Cash Flow: -539.8K Q1 '25 — Net Income: -842.1K Q2 '25 — Operating Cash Flow: -894.2K Q2 '25 — Net Income: -2.3M Q3 '25 — Revenue: 796K Q3 '25 — Operating Cash Flow: -964.7K Q3 '25 — Net Income: -2M Q4 '25 — Operating Cash Flow: -587.6K Q4 '25 — Net Income: -2.8M Q1 '26 — Operating Cash Flow: -894.2K Q1 '26 — Net Income: -1.6M Q2 '26 — Operating Cash Flow: -244.4K Q2 '26 — Net Income: -736.9K -6M -4M -2M 0 2M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 1203.7%
Oper. margin -2201.1%
ROIC -50.5%
Accruals -22.8%
Gross margin 171.9%
Asset turnover 0.015×
EBITDA margin -2191.1%
FCF margin -909.1%
OCF margin -909.1%
ROA -36.6%
ROCE -47.5%
ROE -69.1%
Capex / sales —
OCF / EBIT —
OE margin —
Profit margin —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.3
RPO / sales 0.043×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.5
ND/EBITDA —
Current ratio 0.072×
Interest cover -42.0×
Debt / Eq 0.0×
Debt payback 0.0 yr
Cash runway 0.035 yr
F-score 4.5 pts
Quick ratio 0.07×
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.0
Shares change +72.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales Q/Q —
Sales/sh Y/Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.